Table 3.
PDT studies for meningiomas.
| Type of Study | Authors | Published Year | PS | No. of Patients with a Meningioma (WHO Grade) | Cell Lines | Reference |
|---|---|---|---|---|---|---|
| In vitro | Ichikawa, et al. | 2019 | talaporfin | HKBMM (human MM), KMY-J (rat MM) | [58] | |
| Review | Diez, et al. | 2019 | 5-ALA | [49] | ||
| In vitro | Takahashi, et al. | 2018 | talaporfin | KMY-J (rat MM) | [59] | |
| In vitro | El-Khatib, et al. | 2015 | 5-ALA | 12 (grade I), 1 (grade II) and 1 (grade III) cultured from specimen | [48] | |
| Review | Ishikawa, et al. | 2015 | 5-ALA | [47] | ||
| Review | Bechet, et al. | 2014 | All established PSs before publish date | [57] | ||
| In vitro | Cornelius, et al. | 2014 | 5-ALA | KT21-MG (human MM) | [56] | |
| Review | Nokes, et al. | 2014 | 5-ALA | [55] | ||
| Review | Behbananinia, et al. | 2013 | All established PSs before publish date | [54] | ||
| In vitro | Sun, et al. | 2013 | 5-ALA | IOMM-Lee (human MM) | [53] | |
| Review | Colditz, et al. | 2012 | 5-ALA | [52] | ||
| Review | Hefti, et al. | 2012 | 5-ALA | [51] | ||
| In vitro | Hefti, et al. | 2011 | 5-ALA | HBL-52& BEN-MEN-1 (human benign meningioma) | [50] | |
| Clinical | Eljamel, et al. | 2009 | 5-ALA | 2 (ND) | [46] | |
| Clinical | Muller, et al. | 2006 | Profimer | 3 (MM) | [9] | |
| Clinical | Woehlck, et al. | 2003 | Verteporphin | 1 (MM) | [60] | |
| In vitro | Tsai, et al. | 1999 | 5-ALA | CH-157MN (benign meningioma) | [45] | |
| Review | Devaux, et al. | 1996 | All established PSs before publish date | [61] | ||
| In vitro | Malham, et al. | 1996 | HpD, AIPC | 5 cell lines cultured from specimen (WHO grade: ND) | [62] | |
| In vitro | Wilson, et al. | 1996 | AIPC | 2 cell lines cultured from specimen (WHO grade: ND) | [63] | |
| Clinical | Kostron, et al. | 1995 | HpD | 3(MM) | [43] | |
| Review | Krishnamurthy, et al. | 1994 | HpD | [42] | ||
| Clinical | Origitano, et al. | 1993 | Profimer | 1 (ND) | [44] | |
| In vitro | Marks, et al. | 1992 | HpD | 5 cell lines cultured from specimen (4: grade I, 1: grade II) | [41] | |
| Review | Powers, et al. | 1992 | HpD | [40] | ||
| Clinical | Chen, et al. | 1991 | HpD | 1 (MM) | [39] | |
| In vitro | Plattner, et al. | 1991 | HpD | 1 cell line cultured from specimen (WHO grade: ND) | [38] | |
| In vitro | Steichen, et al. | 1991 | Tritiated-TPP | 3 cell lines cultured from specimen (WHO grade: ND) | [64] | |
| Clinical | Kostron, et al. | 1990 | HpD | 1 (MM) | [8] | |
| Clinical | Kostron, et al. | 1988 | HpD | 1 (MM) | [37] |
5-ALA: 5-aminolevulinic acid, MM: malignant meningioma, HpD: hematoporphyrin derivative, AIPC: aluminum phthalocyanine chloride, TTP: tetraphenylphosphonium, ND: not described.